TMZ, the standard chemotherapeutic agent for glioblastoma, has shown limited efficacy, particularly in the patients lacking O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation or isocitrate dehydrogenase (IDH) mutations [7,9,10]. This evidence concerns the gene MGMT and glioblastoma.